Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016
TMCnet.com,
] Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being investigated in moderate to…
] Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being investigated in moderate to…
Pfizer to Present New Data on XELJANZ ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016 Pfizer Inc.
Pfizer to Present New Data on XELJANZ ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016 NEW YORK — (BUSINESS WIRE…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE ) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being…
NEW YORK --(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being…
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. ( PFE ) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being…
NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being…
NEW YORK--(BUSINESSWIRE)-- Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ ® (tofacitinib citrate), being…
Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being investigated in moderate to…
Oct. 15, 2016 14:30 UTC NEW YORK--( BUSINESS WIRE )-- Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ ® (tofaci…
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced that three abstracts for XELJANZ® (tofacitinib citrate), being…
Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO Pfizer Inc.
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two…
NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first…
Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies…
Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO NEW YORK--(BUSINESS WIRE)-…
Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO NEW YORK --(BUSINESS WIRE)…
Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal…
NEW YORK--(Business Wire)--Pfizer Inc. announced today top-line results from two Phase 3 induction trials of tofacitinib 10 mg…
Pfizer Inc. announced today top-line results from two Phase 3 induction trials of tofacitinib 10 mg twice daily (BID) tablets…